Conference Proceedings

SWATH-MS profiling identifies prognostic factors for progression- free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG)

Sarah A Hayes, Andrew Martin, Sonia Yip, Viive M Howell, Katrin M Sjoquist, Eric Tsobanis, Yoon-Koo Kang, Yung-Jue Bang, Thierry Alcindor, Christopher J O'Callaghan, Niall C Tebbutt, John Simes, David Goldstein, Nick Pavlakis

Cancer Chemistry | AMER ASSOC CANCER RESEARCH | Published : 2019